OmniComm Systems, a provider of software solutions for the life sciences industry, has entered into an agreement with German academic centre KKS (Coordination Center for Clinical Trials) for TrialMaster Electronic Data Capture (EDC) technology.
TrialMaster is designed as an EDC solution to support Phase I-IV clinical trials. Medical professionals can use the platform to collect and manage clinical data.
All forms data can be handled using TrialMaster, including batch-loaded lab and imaging data, data from external systems as well as data directly entered by patients.
The platform also features risk-based monitoring (RBM), data management and analytical tools.
It additionally includes capabilities for query management, operational and clinical reporting, randomisation, clinical adjudication and links to imaging systems.
As per the terms of the multi-year agreement, Heinrich Heine University Düsseldorf will use the OmniComm technology to develop and conduct clinical trials at several sites.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
KKS is a division of the university and is responsible for the clinical trials performed at the institution.
The university will also migrate multiple ongoing trials of the TrialMaster platform, which is expected to improve the efficiency and effectiveness of the KKS trials.
KKS has chosen TrialMaster for its flexibility and capabilities to support trials across all phases of clinical development, said OmniComm.
OmniComm Systems president and CEO Stephen Johnson added: “We are honoured to be partnering with KKS in supporting such a prestigious University as they strive to improve the quality of clinical trials and continue to develop further competence in the academic sector.”